N@N

Market Maker Surveillance Report. UBRG, BX, VLO, SNV, NYB, XOMA, Highest Net Buy Volume With Lowest Price Friction For Thursda

^{Published on 2010-12-23 19:01:26 - WOPRAI}
 

December 23, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 2625 companies with "abnormal" market making, 2417 companies with positive Friction Factors and 2925 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. UNIVERSAL BIOENERGY INC (OTC:UBRG), BLACKSTONE GROUP LP/THE (NYSE:BX), VALERO ENERGY CORP (NYSE:VLO), SYNOVUS FINANCIAL CORP (NYSE:SNV), NEW YORK COMMUNITY BANCORP (NYSE:NYB), XOMA LTD (NASDAQ:XOMA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     UBRG       $0.020       57.43%       2,297,056       66.49%       1,147,470       33.22%       1,149,586       571,933 
     BX         $0.250       1.75%        2,867,125       54.69%       1,807,362       34.47%       1,059,763       42,391  
     VLO        $0.240       1.04%        3,189,539       54.46%       2,112,178       36.06%       1,077,361       44,890  
     SNV        $0.040       1.51%        8,456,046       52.81%       6,408,376       40.02%       2,047,670       511,918 
     NYB        $0.450       2.39%        6,040,574       64.55%       2,590,848       27.68%       3,449,726       76,661  
     XOMA       $2.650       58.89%       16,761,450      52.40%       15,081,244      47.15%       1,680,206       6,340   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a Net Buy Volume of 1,680,206 shares and a Friction Factor of 6,340 shares. That means that it takes 6,340 more shares of buying than selling to move XOMA higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Thursday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

UNIVERSAL BIOENERGY INC (OTC:UBRG) - Universal Bioenergy Inc. operates as an alternative green energy company, which focuses on the production and marketing of alternative energy, including solar, biofuel, wind, and wave energy technologies, as well as related green/chemical technology products. The company was founded in 2007 and is based in Irvine, California.

BLACKSTONE GROUP LP/THE (NYSE:BX) - The Blackstone Group, L.P., together with its subsidiaries, provides alternative asset management and financial advisory services worldwide. The company operates in four segments: Private Equity, Real Estate, Credit and Marketable Alternatives, and Financial Advisory. The Private Equity segment involves in private equity investing through five general private equity funds and one specialized fund focusing on communications-related investments. This segment engages in various transactions comprising leveraged buyout acquisitions of companies, transactions involving start-up businesses in established industries, minority investments, corporate partnerships, distressed debt, structured securities, and industry consolidations. The Real Estate segment manages opportunistic real estate funds, internationally focused real estate funds, European focused real estate fund, and real estate debt investment funds. This segment invests in lodging, urban office buildings, and various real estate operating companies. The Credit and Marketable Alternatives segment engages in the management of funds of hedge funds, credit-oriented funds, CLO vehicles, and publicly-traded closed-end mutual funds. The Financial Advisory segment offers corporate, and mergers and acquisitions advisory services; restructuring and reorganization advisory services; and fund placement services for alternative investment funds. Blackstone Group Management L.L.C. operates as the general partner of the company. The Blackstone Group, L.P. was founded in 1985 and is headquartered in New York, New York.

VALERO ENERGY CORP (NYSE:VLO) - Valero Energy Corporation operates as an independent petroleum refining and marketing company. The company operates through three segments: Refining, Retail, and Ethanol. The Refining segment engages in refining operations, wholesale marketing, product supply and distribution, and transportation operations. This segment produces conventional gasoline, distillates, jet fuel, asphalt, petrochemicals, lubricants, and other refined products, as well as a slate of premium products, including conventional blendstock for oxygenate blending, reformulated gasoline blendstock for oxygenate blending, gasoline meeting the specifications of the California Air Resources Board (CARB), CARB diesel fuel, low-sulfur and ultra-low-sulfur diesel fuel, and oxygenates. This segment owns and operates 15 refineries located in the United States, Canada, and Aruba. The Retail segment sells transportation fuels at retail stores and unattended self-service cardlocks; convenience store merchandise and services in retail stores; and home heating oil to residential customers in the United States and Canada. The Ethanol segment produces ethanol. This segment owns 10 ethanol plants in the Midwest. Valero Energy Corporation markets its refined products through bulk and rack marketing network, and approximately 5,800 retail and wholesale branded outlets in the United States, Canada, and Aruba under various brand names, including Valero, Diamond Shamrock, Shamrock, Ultramar, and Beacon. The company was formerly known as Valero Refining and Marketing Company and changed its name to Valero Energy Corporation in August 1997. Valero Energy Corporation was founded in 1955 and is based in San Antonio, Texas.

SYNOVUS FINANCIAL CORP (NYSE:SNV) - Synovus Financial Corp., a diversified financial services and bank holding company, provides commercial and retail banking, financial management, insurance, and mortgage services in Georgia, Alabama, South Carolina, Florida, and Tennessee. Its retail banking services include accepting customary types of demand and savings deposits; individual, consumer, installment, and mortgage loans; safe deposit services; automated banking services; automated fund transfers; Internet based banking services; and bank credit card services, including mastercard and visa services, as well as commercial banking services comprise commercial, financial, agricultural, and real estate loans. The company also provides various other financial services, which include the portfolio management for fixed-income securities, investment banking, the execution of securities transactions as a broker/dealer, and the provision of individual investment advice on equity and other securities; trust services; mortgage services; financial planning services; and asset management services. Synovus Financial Corp. was founded in 1888 and is headquartered in Columbus, Georgia.

NEW YORK COMMUNITY BANCORP (NYSE:NYB) - New York Community Bancorp, Inc. operates as a multi-bank holding company for New York Community Bank and New York Commercial Bank, which offers banking products and services in New York, New Jersey, Ohio, Florida, and Arizona. It primarily engages in generating deposits and originating loans. The companys deposit products include checking and savings accounts, certificates of deposit, individual retirement accounts, NOW and money market accounts, and non-interest-bearing demand deposit accounts. Its lending portfolio comprises one- to four-family loans; multi-family loans; commercial real estate loans; acquisition, development, and construction loans; commercial and industrial loans; and consumer loans. New York Community Bancorp also provides cash management, online banking, automated teller machine (ATM), and phone banking services. The company serves small and mid-size businesses, professional associations, government agencies, consumers, and school districts. As of December 31, 2009, it operated 241 community bank branches, 35 commercial bank branches, and 289 ATM locations. The company was formerly known as Queens County Bancorp, Inc. and changed its name to New York Community Bancorp, Inc. in November 2000. New York Community Bancorp, Inc. was founded in 1859 and is based in Westbury, New York.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net